Literature DB >> 6601144

Interleukin 2 dependence of human natural killer (NK) cell activity.

W Domzig, B M Stadler, R B Herberman.   

Abstract

When purified populations of human natural killer (NK) cells were tested for cytotoxic activity in the presence of partially purified preparations of human interleukin 2 (IL 2), a definite, dose-dependent linear increase in reactivity was observed. To determine whether such augmentation by IL 2 might reflect an important aspect of the physiologic regulation of NK activity, we examined the effects of monoclonal antibodies against human IL 2 on spontaneous NK activity. The presence of such antibodies during the 4-hr cytotoxicity assay resulted in significant inhibition of NK activity, and when the NK cells were pretreated for 16 to 20 hr with anti-IL 2, little or no activity remained. These data suggest that the spontaneous cytotoxic activity of NK cells is dependent on their continued exposure to IL 2. The reduction in NK activity resulting from treatment with anti-IL 2 could be at least partially restored by exposure to only low amounts of partially purified IL 2. These data have provided the basis for formulating a novel model of NK cell activation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6601144

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Bone marrow and peripheral blood natural killer cell activity in lymphomas. Its response to IL-2.

Authors:  L H Caldera; M Leon-Ponte; G Acquatella; N E Bianco; I Blanca
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

2.  Photoaffinity labeling of ATP and NAD+ binding sites on recombinant human interleukin 2.

Authors:  S Campbell; H Kim; M Doukas; B Haley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

3.  Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells.

Authors:  J H Kehrl; M Dukovich; G Whalen; P Katz; A S Fauci; W C Greene
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

4.  Interleukin 2 enhances natural killing of varicella-zoster virus-infected targets.

Authors:  M Ito; S Bandyopadhyay; M Matsumoto-Kobayashi; S C Clark; D Miller; S E Starr
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

5.  Effects of recombinant interleukin 2 on immunological effector cells of the peripheral blood in patients with HBe antigen-positive chronic hepatitis.

Authors:  Y Mizoguchi; T Shin; Y Sakagami; S Seki; T Kuroki; K Kobayashi; S Yamamoto; S Morisawa
Journal:  Gastroenterol Jpn       Date:  1988-04

6.  A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma.

Authors:  P B Chapman; J E Kolitz; T B Hakes; J L Gabrilove; K Welte; V J Merluzzi; A Engert; E C Bradley; M Konrad; R Mertelsmann
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

7.  The IL-2 receptor beta subunit is absolutely required for mediating the IL-2-induced activation of NK activity and proliferative activity of human large granular lymphocytes.

Authors:  H Umehara; E T Bloom
Journal:  Immunology       Date:  1990-05       Impact factor: 7.397

8.  Clinical studies on cell-mediated immunity in patients with renal cell carcinoma: interleukin-2 and interferon-gamma production of lymphocytes.

Authors:  S Ikemoto; S Wada; M Kamizuru; N Hayahara; T Kishimoto; M Maekawa
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Fetal natural killer cell function is suppressed.

Authors:  E Dominguez; J A Madrigal; Z Layrisse; S B Cohen
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

10.  Mechanism(s) of in vitro macrophage activation with Nocardia rubra cell wall skeleton: the effects on macrophage activating factor production by lymphocytes.

Authors:  T Masuno; S Hayashi; M Ito; T Ikeda; T Ogura; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.